NASDAQ:NEO NeoGenomics (NEO) Stock Forecast, Price & News $16.46 -0.90 (-5.18%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$16.38▼$17.5350-Day Range$14.10▼$19.8352-Week Range$6.00▼$20.54Volume508,129 shsAverage Volume1.08 million shsMarket Capitalization$2.10 billionP/E RatioN/ADividend YieldN/APrice Target$19.55 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NeoGenomics MarketRank™ ForecastAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside18.7% Upside$19.55 Price TargetShort InterestBearish6.20% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.52) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.45 out of 5 starsMedical Sector893rd out of 987 stocksTesting Laboratories Industry1st out of 1 stocks 2.4 Analyst's Opinion Consensus RatingNeoGenomics has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.55, NeoGenomics has a forecasted upside of 18.7% from its current price of $16.46.Amount of Analyst CoverageNeoGenomics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.20% of the outstanding shares of NeoGenomics have been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in NeoGenomics has recently increased by 11.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NEO. Previous Next 2.1 News and Social Media Coverage News SentimentNeoGenomics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for NeoGenomics this week, compared to 4 articles on an average week.Search InterestOnly 12 people have searched for NEO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions88.15% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.52) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -16.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -16.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NeoGenomics (NASDAQ:NEO) StockNeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.Read More Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address NEO Stock News HeadlinesJune 8, 2023 | finance.yahoo.comInvestor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is LackingJune 8, 2023 | americanbankingnews.comNeoGenomics (NASDAQ:NEO) Releases FY 2023 Earnings GuidanceJune 9, 2023 | Vantage Point (Ad)Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. June 7, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on NeoGenomics (NEO)June 6, 2023 | finance.yahoo.comThe Proxies: A celebration of substantial corporate perksJune 5, 2023 | benzinga.comNeoGenomics shares are trading lower after the company announced new data from the Phase 3 PENELOPE-B study at the 2023 ASCO Annual Meeting.June 5, 2023 | finance.yahoo.comNeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast CancerJune 2, 2023 | americanbankingnews.comNeoGenomics, Inc. (NASDAQ:NEO) Receives $19.60 Consensus PT from AnalystsJune 9, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowJune 1, 2023 | finance.yahoo.comNeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare ConferenceMay 30, 2023 | finance.yahoo.comNeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCOMay 18, 2023 | msn.comNeoGenomics: What Lies AheadMay 18, 2023 | americanbankingnews.comNeoGenomics (NASDAQ:NEO) Shares Gap Down to $19.13May 17, 2023 | finance.yahoo.comZacks.com featured highlights include First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy ProductsMay 17, 2023 | americanbankingnews.comPiper Sandler Boosts NeoGenomics (NASDAQ:NEO) Price Target to $23.00May 16, 2023 | benzinga.comNeoGenomics shares are trading lower after Raymond James downgraded the stock from Outperform to Market Perform.May 16, 2023 | msn.comRaymond James Downgrades Neogenomics (NEO)May 16, 2023 | finance.yahoo.com3 Best Breakout Stocks to Invest in for Superlative ReturnsMay 16, 2023 | americanbankingnews.comNeoGenomics (NASDAQ:NEO) Stock Rating Lowered by Raymond JamesMay 15, 2023 | msn.comNeoGenomics's Return On Capital Employed InsightsMay 14, 2023 | msn.com5 Huge Analyst CallsMay 12, 2023 | msn.comNeoGenomics: Q1 Earnings InsightsMay 11, 2023 | markets.businessinsider.comAnalyst Expectations for NeoGenomics's FutureMay 10, 2023 | finanznachrichten.deNeoGenomics, Inc.: NeoGenomics Reports First Quarter 2023 ResultsMay 10, 2023 | washingtonpost.comNeoGenomics: Q1 Earnings SnapshotMay 10, 2023 | msn.comBTIG Upgrades Neogenomics (NEO)May 10, 2023 | finance.yahoo.comNeoGenomics Reports First Quarter 2023 ResultsSee More Headlines NEO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEO Company Calendar Last Earnings11/04/2021Today6/09/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Testing laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NEO CUSIPN/A CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,100Year Founded2002Price Target and Rating Average Stock Price Forecast$19.55 High Stock Price Forecast$25.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+18.7%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-144,250,000.00 Net Margins-23.72% Pretax Margin-26.41% Return on Equity-7.34% Return on Assets-4.23% Debt Debt-to-Equity Ratio0.55 Current Ratio6.75 Quick Ratio6.47 Sales & Book Value Annual Sales$509.73 million Price / Sales4.12 Cash FlowN/A Price / Cash FlowN/A Book Value$7.90 per share Price / Book2.08Miscellaneous Outstanding Shares127,580,000Free Float125,919,000Market Cap$2.10 billion OptionableOptionable Beta1.10 Social Links Key ExecutivesChris SmithChief Executive Officer & DirectorJeffrey Scott ShermanChief Financial OfficerSteven A. RossChief Information Officer & Vice PresidentDavid SholehvarPresident-Clinical ServicesJohn MooneyChief Technology OfficerKey CompetitorsNuVasiveNASDAQ:NUVAHUTCHMEDNASDAQ:HCMHarmony BiosciencesNASDAQ:HRMYNational VisionNASDAQ:EYEGoodRxNASDAQ:GDRXView All CompetitorsInstitutional OwnershipMacquarie Group Ltd.Bought 55,780 shares on 6/1/2023Ownership: 1.587%ProShare Advisors LLCSold 1,618 shares on 5/26/2023Ownership: 0.014%Thrivent Financial for LutheransSold 4,387 shares on 5/17/2023Ownership: 0.098%Sunbelt Securities Inc.Sold 26,511 shares on 5/17/2023Ownership: 0.002%Jane Street Group LLCSold 9,600 shares on 5/16/2023Ownership: 0.000%View All Institutional Transactions NEO Stock - Frequently Asked Questions Should I buy or sell NeoGenomics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NEO shares. View NEO analyst ratings or view top-rated stocks. What is NeoGenomics' stock price forecast for 2023? 11 Wall Street analysts have issued twelve-month price objectives for NeoGenomics' shares. Their NEO share price forecasts range from $15.00 to $25.00. On average, they predict the company's stock price to reach $19.55 in the next year. This suggests a possible upside of 18.7% from the stock's current price. View analysts price targets for NEO or view top-rated stocks among Wall Street analysts. How have NEO shares performed in 2023? NeoGenomics' stock was trading at $9.24 at the beginning of 2023. Since then, NEO shares have increased by 78.1% and is now trading at $16.46. View the best growth stocks for 2023 here. When is NeoGenomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our NEO earnings forecast. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings results on Thursday, November, 4th. The medical research company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The medical research company had revenue of $121.30 million for the quarter, compared to analyst estimates of $125.09 million. NeoGenomics had a negative net margin of 23.72% and a negative trailing twelve-month return on equity of 7.34%. The firm's quarterly revenue was down 3.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.04 earnings per share. What ETFs hold NeoGenomics' stock? ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Services ETF (XHS), Invesco DWA Healthcare Momentum ETF (PTH), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), WisdomTree BioRevolution Fund (WDNA), Vanguard S&P Small-Cap 600 Value ETF (VIOV), SPDR S&P 600 Small CapValue ETF (SLYV) and iShares S&P Small-Cap 600 Value ETF (IJS). What guidance has NeoGenomics issued on next quarter's earnings? NeoGenomics issued an update on its FY 2023 earnings guidance on Wednesday, June, 7th. The company provided earnings per share (EPS) guidance of -$0.36--$0.30 for the period, compared to the consensus EPS estimate of -$0.42. The company issued revenue guidance of $555.00 million-$565.00 million, compared to the consensus revenue estimate of $549.82 million. What is Douglas M. VanOort's approval rating as NeoGenomics' CEO? 116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV). What is NeoGenomics' stock symbol? NeoGenomics trades on the NASDAQ under the ticker symbol "NEO." Who are NeoGenomics' major shareholders? NeoGenomics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Brown Advisory Inc. (5.17%), State Street Corp (3.83%), Greenhouse Funds LLLP (2.30%), First Light Asset Management LLC (2.12%), Dimensional Fund Advisors LP (2.11%) and Geode Capital Management LLC (1.97%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello. View institutional ownership trends. How do I buy shares of NeoGenomics? Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NeoGenomics' stock price today? One share of NEO stock can currently be purchased for approximately $16.46. How much money does NeoGenomics make? NeoGenomics (NASDAQ:NEO) has a market capitalization of $2.10 billion and generates $509.73 million in revenue each year. The medical research company earns $-144,250,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. How many employees does NeoGenomics have? The company employs 2,100 workers across the globe. Does NeoGenomics have any subsidiaries? The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.Read More How can I contact NeoGenomics? NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237. This page (NASDAQ:NEO) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.